41 results about "Cancer imaging" patented technology

The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.

Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells.

A method for imaging cancer using a combined PET-MRI system takes advantage of the performance characteristics for both PET and MRI in the context of cancer imaging. MRI is used to assess a large area of the body with high sensitivity for cancer and PET is then used in localized areas of concern to provide physiological information. Optionally, MRI may also then be used to re-scan the localized areas of concern with high spatial resolution and additional tissue contrasts to provide anatomical information and soft tissue contrast to supplement the PET information. The use of a combined PET-MRI system ensures that the imaging data from both modalities is accurately referenced to the same locations in the body.

The present invention provides compositions comprising a biological agent, a targeting moiety, and a peptide linker attaching the biological agent to the targeting moiety, wherein the peptide linker is selectively cleaved by a protease. Efficient methods are provided for administering the compositions of the present invention for treating cancer or imaging a tumor, organ, or tissue in a subject. Kits are also provided for administering the compositions of the present invention for radiotherapy or radioimaging.

The invention relates to an amphiphilic illuminant with aggregation induced emission characteristics and applications thereof. The illuminant is prepared by connecting a hydrophilia unit on a classical hydrophobicity unit of the classical aggregation induced emission characteristics (AIE), and can be applied to a fluorescent light chemical sensor and is used for preparing fluorescent light coloring agent which is used for coloring living cells and animal imaging fluorescent light. The amphiphilic coloring agent is specifically suitable for the fluorescent light mark on biopolymer, and can be used as a biocompatibility probe for AIE activation so that the amphiphilic coloring agent can be applied to clinic cancer imaging, diagnose and treatment.

The invention provides modified gold nanoparticles that enable a non-invasive, real time, targeted cancer imaging-therapeutic in one step. After reaching the cancer targets, the designed targeted gold nanoparticles significantly enhance conventional treatment modalities at the cellular level. In this aspect the gold nanoparticles of the invention are modified to be bound to a Positron Emission Tomography (PET) tracer.

The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.

Automatic prostate localization in T2-weighted MR images facilitate labor-intensive cancer imaging techniques. Methods and systems to accurately segment the prostate gland in MR images are provided and address large variations in prostate anatomy and disease, intensity inhomogeneities, and artifacts induced by endorectal coils. A center of the prostate is automatically detected with a boosted classifier trained on intensity based multi-level Gaussian Mixture Model Expectation Maximization (GMM-EM) segmentations of the raw MR images. A shape model is used in conjunction with Multi-Label Random Walker (MLRW) to constrain the seeding process within MLRW.

Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.

This invention relates generally to cyanine-containing compounds; pharmaceutical compositions comprising cyanine-containing compounds; and methods of using cyanine-containing compounds for cancer cell imaging, cancer cell growth inhibition, and detecting cancer cells, for example. Compounds of the invention are preferentially taken up by cancer cells as compared to normal cells. This allows many uses in the cancer treatment, diagnosis, tracking and imaging fields.

Compounds having a structure of Formula I:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

The invention discloses a door control type medicine composition integrating cancer imaging and phototherapy and a preparation method. The preparation method comprises the following steps: (1) preparing CuS@mSiO2 nano particles in a core-shell structure; (2) preparing ammoniated CuS@mSiO2 nano particles; and (3) preparing CuS@mSiO2-TD / ICG. Each CuS@mSiO2 nano particle in the core-shell structure, prepared in the invention, is provided with a silicon dioxide shell with a suitable thickness, so that the common load of indocyanine green and TD can be guaranteed; the CuS@mSiO2-TD / ICG can well play a preferable door control role, and the release of indocyanine green is controlled; and during systemic circulation, the effect of opto-thermodynamics and photodynamics combination therapy is achieved. The door control type medicine composition has good water solubility and biocompatibility. The therapeutic effect of tumors can be effectively strengthened, and the toxic and side effects are reduced. The preparation technology is simple, the method is stable and reliable, the reaction controllability is high, and the used raw materials are easily obtained and are low in cost.

Compounds having a structure of Formula I:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.

The present invention relates to an auxiliary evaluation system and method for prognosis and chemotherapy benefit of gastric cancer based on enhanced CT imaging omics. A system and method of that present invention include extracting 19 image texture and morphological characteristic data of gastric cancer focus areas on enhanced CT portal vein phase images of gastric cancer objects, calculating gastric cancer imaging omics score GC Rad-score of each object, and extracting the image texture and morphological characteristic data of the gastric cancer focus areas on the enhanced CT portal vein phase images of the gastric cancer objects. Score, according to the score, predicts the prognosis and chemotherapy benefit after tumor resection and provides credible predictive and analytical results for specific individuals. The system and method of the invention are based on GC Rad-score score can be used to evaluate the prognosis and chemotherapy benefit after gastric cancer surgery. The procedure is simple, intuitive and easy to repeat. The system and method of the invention can evaluate the postoperative prognosis and chemotherapy benefit of gastric cancer, and better assist doctors to formulate treatment and follow-up plan.

Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula:R1 includes a chelating agent that is chelated to a metal atom, wherein the metal atom is a positron or single photon emitting metal isotope with a half life of greater than or equal to 4 hours, or an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2.

A dye-drug conjugate for preventing, treating, or imaging cancer having the following structure:wherein R1 and R2 are independently selected from the group consisting of —H, alkyl, alkyl-sulphonate, alkylcarboxylic, alkylamino, aryl, —SO3H, —PO3H, —OH, —NH2, and -halogen; wherein Y1 and Y2 is independently selected from the group consisting of alkyl, aryl, aralkyl, alkylsulphonate, alkylcarboxylic, alkylamino, ω-alkylaminium, ω-alkynyl, PEGyl, PEGylcarboxylate, ω-PEGylaminium, ω-acyl-NH, ω-acyl-lysinyl-, ω-acyl-triazole, ω-PEGylcarboxyl-NH—, ω-PEGylcarboxyl-lysinyl, and ω-PEGylcarboxyl-triazole; wherein X is selected from the group consisting of a hydrogen, halogen, CN, Me, NH2, SH and OH; and R3 and R4 are independently a hydrogen, a therapeutic agent, or an imaging moiety, wherein the therapeutic agent is selected from the group consisting of a platinum-based therapeutic agent, a small molecule therapeutic agent, a peptide, a protein, a polymer, an siRNA, a microRNA, and a nanoparticle, wherein the imaging is a radio-isotope selected from the group consisting of F18, I-125, I-124 I-123, I-131, and small molecule labeled with any of these isotopes, or wherein the imaging moiety is a chelator-complexed radioactive isotope, wherein the radioactive isotope is selected from the group consisting of Cu-64, In-111, Tc-99m, Ga-68, Lu-177, Zo-89, Th-227 and Gd-157.

The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.

The invention discloses a protein-dye complex and an application thereof. The protein-dye complex comprises human serum albumin and a heptamethine Indocyanine derivative, wherein human serum albumin is used as a carrier, the heptamethine cyanine derivative is adsorbed on the carrier via hydrophobic interaction; the molar ratio of human serum albumin to the heptamethine cyanine derivative is 1:1; the human serum albumin has a molecular weight of 69 KDa; the heptamethine cyanine derivative has a molecular weight of 983.5 Da; and the protein-dye complex has a particle size of 8-10 nanometers. The nanoparticle has high optical absorption property in near-infrared region and strong fluorescence in visible light region, has good dispersibility, and can be used for preparing cancer imaging diagnosis and treatment preparations.

The invention discloses a preparation method of a near-infrared fluorescent compound which accurately targets tumor cells and is activated by beta-galactosidase, wherein the structure of the fluorescent compound is shown in a formula I. The probe compound combines a substrate alphaD-galactose (alphaD-gal) recognized by beta-galactosidase with cyanine near-infrared fluorophores to introduce an alphavbeta3-integrin receptor-targeted ligand c-RGD. The ability of the ligand c-RGD targeting tumor cells is utilized for near-infrared imaging of live mouse tumors overexpressing beta-galactosidase. Theprobe has the advantages that receptor-mediated cell uptake and molecular target activation are combined to realize real-time and non-invasive detection of beta-galactosidase in living tissues. The probe can be successfully applied to improve cancer imaging and promote effective cancer diagnosis.

The invention discloses an intermediate-advanced stage cancer imaging detecting system and an intermediate-advanced stage cancer imaging detecting method based on the quantum superstring engine, mainly used for overcoming the defect that the traditional medical device can not efficiently, safely, rapidly and comprehensively detect the cancer cell spreading area of a cancer patient. The intermediate-advanced stage cancer imaging detecting system comprises a quantum light emission source, an optical splitter, a convex lens, a light filter group, a detection unit, an image processing unit and a display. The intermediate-advanced stage cancer imaging detecting method comprises the steps that orthogonal polarized photons generated by the quantum light emission source pass through the optical splitter, and then are transmitted in two paths; one path of the orthogonal polarized photons irradiates the body of the patient through the convex lens and light filters, penetrates through the body and then is received by a detector, and the other path of the orthogonal polarized photons directly passes through the light filters, and are received by another detector; the detection unit carries out combined measurement on the photons detected by the two detectors, and outputs a detection result to the image processing unit, the image processing unit draws a diffusion area imaging picture of cancer cells in the body of the patient, and the diffusion area imaging picture is displayed by the display. With the adoption of the intermediate-advanced stage cancer imaging detecting system and the intermediate-advanced stage cancer imaging detecting method, the diffusion area imaging picture of the cancer cells can be obtained, and thus a basis is provided for the treatment and research on the cancer patient.

Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter and astrocyte elevated gene 1 (AEG-1) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols, e.g. for imaging and / or treating spontaneous metastasis. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.

The invention provides a novel multi-modal fusion auxiliary diagnosis method based on rectal cancer imaging omics research. The method comprises the following steps of: 1, acquiring medical images ofmultiple modes of rectal cancer, and preprocessing the medical images; 2, segmenting the preprocessed medical image into layers, and obtaining a region of interest corresponding to each layer of medical image; 3, performing feature extraction on each region of interest of each modal medical image, so that corresponding high-dimensional image omics features can be obtained; 4, randomly dividing theobtained samples and correspondingly obtained high-dimensional image omics features to obtain a training set and a test set, and performing feature dimension reduction in training group data; 5, respectively constructing image omics labels based on T2 weighted imaging, diffusion weighted imaging and low-dimensional image omics characteristics of the CT image; and 6, carrying out coefficient weighting on each obtained label, and carrying out linear combination to obtain a multi-modal fusion imaging omics score for rectal cancer auxiliary diagnosis.

The cancer-imaging agent and method of radioimaging relates to the use of a radioimaging agent for the imaging increased choline uptake to detect cancerous tissue. The radioimaging agent includes choline or a pharmaceutically acceptable salt thereof labeled with technetium-99m. Preferably, the radioimaging agent is [methyl]-choline chloride labeled with 99mTcO4, which carries technetium-99m. In use, a patient is administered an effective amount of the radioimaging agent by injection and then scanned with a radioimaging device. The radioimaging agent is used to image select soft tissues in the patient, such as the liver or gallbladder, the upper abdominal organs, or the like, and to detect increased choline uptake. Choline is known to accumulate in cancerous cells. Thus, the radioimaging agent is particularly effective in the detection of potentially cancerous tissues.

The invention comprises a fiducial marker—fiducial detector based treatment room position determination / positioning system apparatus and method of use thereof. A set of fiducial markers and fiducial detectors are used to mark / determine relative position of static and / or moveable objects in a treatment room using photons passing from the markers to the detectors. Further, position and orientation of at least one of the objects is calibrated to a reference line, such as a zero-offset beam treatment line passing through an exit nozzle, which yields a relative position of each fiducially marked object in the treatment room. Treatment calculations are subsequently determined using the reference line and / or points thereon. The treatment calculations are optionally and preferably performed without use of an isocenter point, such as a central point about which a treatment room gantry rotates, which eliminates mechanical errors associated with the isocenter point being an isocenter volume in practice.

Methods are provided for cancer and pre-cancer detection by increased uptake of fluorophore glucose or deoxyglucose conjugates in cancerous and pre-cancerous cells relative to normal cells.

Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided.

The present invention relates to a conjugated compound comprising a marker M pharmaceutically acceptable, and a peptide or pseudo-peptide P having at most 30 amino acid residues and able to bind the Low-Density Lipoprotein Receptor (LDLR) and to its use in a method of labelling and / or detecting and / or treating cancerous cells in a subject by administration of the conjugated compound to the subject an analysis of the presence and / or the amount of marker.